Perceived high risk of COVID-19 vaccination: the revealing power of placebo.

Elsevier

Available online 24 March 2023

The Journal of Allergy and Clinical Immunology: In PracticeAuthor links open overlay panelMichiel Beyens MD 1 2, Alessandro Toscano MD 1 2, Pierre Van Damme MD, PhD 3, Jean-Michel Dogné PhD 4, Didier Ebo MD, PhD 1 2 5, Vito Sabato MD, PhD 1 2 5Show moreKeywords

COVID-19

vaccine

hypersensitivity

allergy

placebo

Recommended articles

Funding and acknowledgement

DE is a senior clinical researcher of the Research Foundation Flanders/Fonds Wetenschappelijk Onderzoek (FWO: 1800614N). VS is a senior clinical researcher of the Research Foundation Flanders/Fonds Wetenschappelijk Onderzoek (FWO: 1804518N).

We would like to thank Mr. T. De Cloet and Mrs. K. Vanbillemont for their efforts during the COVID-pandemic and their aid in the collection of this data.

The authors declare no conflict of interest in relation to this work.

Informed consent was obtained from the participants of this study.

This study was approved by the local Ethics board.

Clinical implication box

The use of a placebo as an additional diagnostic step in the allergological work-up of suspected hypersensitivity reactions can be of great value. In this study, nearly 1 in 3 patients had symptoms after administration of placebo.

View Abstract

© 2023 Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology

Recommended articlesArticle Metrics

留言 (0)

沒有登入
gif